Stock CUBT CURATIVE BIOTECHNOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Curative Biotechnology, Inc.

Equities

CUBT

US23128N2071

Biotechnology & Medical Research

Delayed OTC Markets
Other stock markets
 17:25:50 02/07/2024 BST 		5-day change 1st Jan Change
0.0138 USD -5.78% Intraday chart for Curative Biotechnology, Inc. -12.03% -34.74%
2021 Curative Biotechnology, Inc. Appoints Marc Drimer to Board of Directors as Independent Director and Chairman of Audit Committee CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023
Capitalization 1 0.7263 9.749 29.41 11.43 13.47
Enterprise Value (EV) 1 0.8511 10.15 28.74 12.5 15.67
P/E ratio 6.05 x -2.11 x -1.44 x -2.09 x -2.42 x
Yield - - - - -
Capitalization / Revenue - - - - -
EV / Revenue - - - - -
EV / EBITDA -5,674 x -2.21 x -5.75 x -2.86 x -8.51 x
EV / FCF - - 13,343,280 x 23,129,645 x -7,599,694 x
FCF Yield - - 0% 0% -0%
Price to Book -8.21 x -2.22 x -1.88 x -4.5 x -6.12 x
Nbr of stocks (in thousands) 322,800 322,800 544,542 571,652 632,494
Reference price 2 0.002250 0.0302 0.0540 0.0200 0.0213
Announcement Date 24/11/21 24/11/21 15/04/22 06/05/24 06/05/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023
Net sales - - - - -
EBITDA 1 -0.00015 -4.598 -4.997 -4.371 -1.843
EBIT 1 -0.005451 -4.604 -4.997 -4.463 -1.933
Operating Margin - - - - -
Earnings before Tax (EBT) 1 0.2072 -4.67 -5.34 -5.38 -3.957
Net income 1 0.2072 -4.67 -5.34 -5.38 -3.957
Net margin - - - - -
EPS 2 0.000372 -0.0143 -0.0376 -0.009560 -0.008785
Free Cash Flow - - 2.154 0.5404 -2.062
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 24/11/21 24/11/21 15/04/22 06/05/24 06/05/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023
Net Debt 1 0.12 0.4 - 1.07 2.2
Net Cash position 1 - - 0.67 - -
Leverage (Debt/EBITDA) -832 x -0.0868 x - -0.2439 x -1.195 x
Free Cash Flow - - 2.15 0.54 -2.06
ROE (net income / shareholders' equity) - -613% -325% 1,256% 139%
ROA (Net income/ Total Assets) - -249% -133% -125% -51.8%
Assets 1 - 1.878 4.006 4.315 7.641
Book Value Per Share 2 -0 -0.0100 -0.0300 -0 -0
Cash Flow per Share - 0 0 0 0
Capex - - 0.01 - -
Capex / Sales - - - - -
Announcement Date 24/11/21 24/11/21 15/04/22 06/05/24 06/05/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CURATIVE BIOTECHNOLOGY, INC. Stock Curative Biotechnology, Inc.
-34.74% 13.28M
MODERNA, INC. Stock Moderna, Inc.
+16.52% 44.44B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-9.94% 37.99B
LONZA GROUP AG Stock Lonza Group AG
+37.55% 37.75B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+30.08% 30.78B
CELLTRION, INC. Stock Celltrion, Inc.
-8.44% 27.38B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.21% 26.17B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+44.81% 14.15B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.30% 12.59B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.43% 11.28B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CUBT Stock
  4. Financials Curative Biotechnology, Inc.